Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
Laurie H. Sehn, Maurizio Martelli, Marek Trnĕný, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 120

Showing 1-25 of 120 citing articles:

2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management
Sandra Susanibar‐Adaniya, Stefan K. Barta
American Journal of Hematology (2021) Vol. 96, Iss. 5, pp. 617-629
Open Access | Times Cited: 253
Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
Rena Liu, Robert J. Oldham, Emma Teal, et al.
Antibodies (2020) Vol. 9, Iss. 4, pp. 64-64
Open Access | Times Cited: 166
Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics
Jan Škubník, Vladimíra Svobodová Pavlíčková, Tomáš Ruml, et al.
Biology (2021) Vol. 10, Iss. 9, pp. 849-849
Open Access | Times Cited: 107
Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies
Josée Golay, Alain E. Andrea, Irene Cattaneo
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 51
PET/CT in Non-Hodgkin Lymphoma: An Update
Lucia Zanoni, Davide Bezzi, Cristina Nanni, et al.
Seminars in Nuclear Medicine (2022) Vol. 53, Iss. 3, pp. 320-351
Closed Access | Times Cited: 42
Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells
Agnieszka Dąbkowska, Krzysztof Domka, Małgorzata Firczuk
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
Hilma J. van der Horst, Inger S. Nijhof, Tuna Mutis, et al.
Cancers (2020) Vol. 12, Iss. 10, pp. 3041-3041
Open Access | Times Cited: 54
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination
Thomas E. Lew, John F. Seymour
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 36
Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
Prokop Vodička, Pavel Klener, Marek Trnĕný
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1481-1501
Open Access | Times Cited: 33
FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects
Akram Al‐Ibraheem, Ahmed Saad Abdlkadir, Malik E. Juweid, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1063-1063
Open Access | Times Cited: 19
2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma
Montreh Tavakkoli, Stefan K. Barta
American Journal of Hematology (2023) Vol. 98, Iss. 11, pp. 1791-1805
Open Access | Times Cited: 19
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
Adam J. Olszewski, Tycel Phillips, Marc Hoffmann, et al.
Blood Advances (2023) Vol. 7, Iss. 20, pp. 6055-6065
Open Access | Times Cited: 16
Anti-CD20 treatment for B-cell malignancies: current status and future directions
Christian Klein, Candice Jamois, Tina Nielsen
Expert Opinion on Biological Therapy (2020) Vol. 21, Iss. 2, pp. 161-181
Open Access | Times Cited: 43
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study
Lale Kostakoglu, Federico Mattiello, Maurizio Martelli, et al.
Haematologica (2021) Vol. 107, Iss. 7, pp. 1633-1642
Open Access | Times Cited: 36
Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review
Andrew Davies, Arnon P. Kater, Jeff P. Sharman, et al.
Future Oncology (2022) Vol. 18, Iss. 26, pp. 2943-2966
Open Access | Times Cited: 22
Modulating antibody effector functions by Fc glycoengineering
Mikel García-Alija, Berre Van Moer, Diego E. Sastre, et al.
Biotechnology Advances (2023) Vol. 67, pp. 108201-108201
Open Access | Times Cited: 13
Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma
Clémentine Sarkozy, Mary Callanan, Catherine Thiéblemont, et al.
Blood (2024) Vol. 144, Iss. 3, pp. 262-271
Closed Access | Times Cited: 5
The future of immunotherapy for diffuse large B‐cell lymphoma
Johannes Duell, Jason R. Westin
International Journal of Cancer (2024) Vol. 156, Iss. 2, pp. 251-261
Open Access | Times Cited: 5
Диффузная В-крупноклеточная лимфома с высоким риском поражения центральной нервной системы (обзор литературы, вопросы профилактики, лечение, прогноз)
Сельми Фаиковна Рамазанова, А. В. Аракелян, Anna Semenova, et al.
Clinical oncohematology (2025) Vol. 18, Iss. 1, pp. 51-64
Open Access
gneSeqCOO: a novel method for classifying diffuse large B-cell lymphoma cell of origin based on bulk tumor RNA sequencing profiles
Will Harris, Yi Cao, Franck Morschhauser, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-8
Open Access
Definitions and use of tumour bulk in phase 3 lymphoma trials: a comprehensive literature review
Luke Wang, Eliza Chung, Cameron Wellard, et al.
Blood Advances (2025)
Open Access
Is first-line treatment with polatuzumab vedotin–rituximab–cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model
Liangliang Dong, Wanfu Zhong, Ting Chen, et al.
BMJ Open (2025) Vol. 15, Iss. 1, pp. e086251-e086251
Open Access
Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present
Jacob Naman, Nihar Shah, Benjamin Heyman
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1711-1711
Open Access
Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice
Elaine S. Jaffe, Paul M. Barr, Sonali M. Smith
American Society of Clinical Oncology Educational Book (2017), Iss. 37, pp. 535-546
Open Access | Times Cited: 43
DLBCL 1L—What to Expect beyond R-CHOP?
Maike Stegemann, Sophy Denker, Clemens A. Schmitt
Cancers (2022) Vol. 14, Iss. 6, pp. 1453-1453
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top